Medicine, Health Care and Philosophy

, Volume 16, Issue 2, pp 305–309 | Cite as

Big pharma: a story of success in a market economy

Practical Viewpoint

Abstract

In this paper, I will argue that the current discussions about regulating certain activities concerning the pharmaceutical industry do miss a crucial point. The Pharmaceutical Industry is a story of success, providing a wealth of new discoveries and applied technologies, which have greatly enhanced our lives. The current call for strict regulation of the Pharmaceutical Industry makes the unwarranted assumption that such regulation will not disturb the mechanisms of the Industry’s success. I will claim that a centralised regulation profoundly transforms the direction of travel. I will also claim that the role of the executive in bypassing regulations creates a parallel industry of subsidiary regulations to counter such bypassing. The predictable consequence is the increasing role of central regulatory control and the progressive slowing down of the success of the Pharmaceutical Industry leading towards an undesirable mediocrity. The conclusion I wish to advance is that our choices are not limited to ‘a wild open market’ and ‘a regulated open market’ scenarios, and the strategy to avoid a robustly regulated but mediocre Pharmaceutical Industry may involve ‘non-open market scenarios’ which have so far been absent from the alternatives discussed.

Keywords

Bureaucracy Central planning Executive role/motivation/behaviour Ideology Pharmaceutical industry Political economy of health Regulation 

References

  1. Ali, M. 2010. London mental health commissioning development network presentation. From London Development Centre: http://www.londondevelopmentcentre.org/cms/site/docs/Presentation%20by%20Dr%20Mo%20Ali.pdf. Retrieved 19 Oct 2011.
  2. British Medical Association. 2010. BMA Response to the health white paper. From British Medical Association: http://www.bma.org.uk/healthcare_policy/nhs_white_paper/whitepaperbmabriefingpaper.jsp. Retrieved 19 Oct 2011.
  3. Department of Health. 2010. Equity and excellence: Liberating the NHS. From Department of Health: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_117794.pdf. Retrieved 19 Oct 2011.
  4. Doyal, L. 1985. The political economy of health. London: Pluto Press Limited.Google Scholar
  5. Iacobucci, G., and E. Slater. 2011. Half on some Consortia have links to Virgin Group. Pulse 71(21): 1.Google Scholar
  6. Kelman, S. 1975. The social nature of the definition problem of health. International Journal of Health Services 5: 625–642.PubMedCrossRefGoogle Scholar
  7. Krause, D. 1995. Sun-Tzu—the art of war for executives. London: Nicholas Brealey Publishing.Google Scholar
  8. Lawrence, F. 2004. Not on the label. London: Penguin Books.Google Scholar
  9. Moynihan, R. 2010. Who benefits from treating prehypertension? BMJ 341: c4442.Google Scholar
  10. Moynihan, R., P. Gøtzsche, I. Heath, and D. Henry. 2002. Selling sickness: the pharmaceutical industry and disease mongering. BMJ 324: 886.1Google Scholar
  11. NHS Quality Improvement Scotland. 2008. Geting relevant information on pain services. From National Pain Audit: http://nationalpainaudit.org/media/files/GRIPS_booklet.pdf. Retrieved 19 Oct 2011.
  12. Oxfam International. 2002. Mugged: poverty in your coffee cup. From make trade fair: http://www.maketradefair.com/en/index.php?file=16092002164814.htm. Retrieved 19 Oct 2011.
  13. Westin, S., and I. Heath. 2005. Thresholds for normal blood pressure and serum cholesterol. BMJ 330: 1461.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  1. 1.LiberCare LtdNotts, MansfieldUK
  2. 2.The Corner SurgeryLondonUK

Personalised recommendations